Prometic Life Sciences Inc., of Laval, Quebec, said it completed its equity rights offering, raising CA$37.99 million (US$28.35 million). The company will use the proceeds to finance ongoing operations, which include the plasma-derived therapeutics segment, small-molecule therapeutics segment and corporate functions.